Hepatitis Therapeutics Market: Market Size & Forecast 2026

The global hepatitis therapeutics market encompasses antiviral medications, vaccines, and emerging biologics targeting hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, which together affect hundreds of millions of people worldwide. The market is valued at approximately $19.34 billion in 2025 and is expected to expand at a compound annual growth rate of 5.4%, driven by the persistent global disease burden, improving treatment access, and continued innovation in drug development.

• •Hepatitis B chronically infects an estimated 296 million people globally, while approximately 58 million people live with chronic hepatitis C infection
• •Hepatitis C has seen a therapeutic revolution with direct-acting antivirals achieving cure rates above 95%, though access gaps remain in low-income regions
• •Hepatitis B remains a major unmet need as current antiviral therapies suppress viral replication but rarely achieve functional cure

A primary catalyst for market expansion is the high and largely undertreated global prevalence of chronic viral hepatitis, particularly hepatitis B in the Asia-Pacific and African regions. Rising government and non-profit initiatives focused on screening, diagnosis, and treatment access are expanding the patient pool receiving care. Additionally, growing adoption of novel antiviral agents and the introduction of combination therapies targeting hepatitis B functional cure are expected to drive premium pricing and volume growth.

• •The World Health Organization estimates that viral hepatitis caused 1.3 million deaths in 2022, underscoring the urgent need for expanded treatment
• •National elimination programs in countries including China, India, and Brazil are accelerating treatment scale-up for chronic hepatitis
• •Increased healthcare spending and insurance coverage expansion in emerging markets are improving patient access to expensive specialty therapies

The market is segmented primarily by disease type, with hepatitis B and hepatitis C representing the largest therapeutic segments, alongside vaccines for hepatitis A and B prevention. By product class, antivirals and vaccines dominate, while emerging categories such as RNA-based therapies and immunomodulators are gaining traction. Geographically, Asia-Pacific holds the largest share due to the high disease burden, followed by North America and Europe, where advanced healthcare infrastructure supports adoption of premium-priced therapies.

• •North America benefits from favorable reimbursement policies and high treatment rates, while Asia-Pacific represents the fastest-growing region driven by population size and rising disease awareness
• •The hepatitis B therapeutics segment is larger than hepatitis C due to the chronic nature of HBV infections and the lack of a definitive cure
• •Vaccines, particularly for hepatitis B, account for a significant and stable revenue stream, especially in pediatric and high-risk adult immunization programs

What are the recent trends and outlook?

The market outlook reflects a transition from the hepatitis C eradication era toward an intensified focus on hepatitis B functional cure research, with numerous late-stage clinical trials evaluating combination antiviral and immunotherapeutic approaches. Advances in RNA therapeutics, including small interfering RNA and antisense oligonucleotides, are opening new avenues for durable HBV suppression and potential functional cure. Over the forecast period, pricing pressures from generic hepatitis C entrants and health technology assessments will be offset by premium pricing for innovative hepatitis B therapies entering the market.

• •The hepatitis C market faces gradual revenue decline as more patients achieve cure and generic competition intensifies, redirecting industry focus toward the larger hepatitis B opportunity
• •Long-acting injectable formulations and combination single-tablet regimens are being developed to improve adherence and patient outcomes in chronic hepatitis management
• •Public-private partnerships and volume-based pricing agreements are expected to expand treatment access in low- and middle-income countries, particularly in sub-Saharan Africa and Southeast Asia